A combination of the clinical criterion, which is related to the cognitive domain of memory, and a multimodal approach based on cerebrospinal fluid (CSF concentrations of tau and Aß42) and neuroimaging biomarkers (PET - 18FDG, PET Aβ and tau, MRI volume of the hippocampus and cortical thickness) will play a decisive role in large-scale drug trials of preclinical and prodromal AD. Here, MAPT is linked to Alzheimer disease.